Market MapHormonal
Menopause Ecosystem
Pharma, virtual care, devices, and consumer brands competing across menopause — plotted on clinical depth vs. consumer reach.
Overview
Astellas (Veozah) and Bayer (Lynkuet) are racing in non-hormonal pharma; Midi Health and Evernow lead virtual care; Embr Labs and Winona expand in devices and DTC HRT.
Menopause is now a category with marketed pharma, unicorn virtual clinics, and a fast-growing OTC layer.
Competitive positioning
2×2 matrix
Each tile links to a company profile when one exists. Axes reflect clinical depth and consumer reach.
↑ Clinical depth / Regulatory maturity
High ← Clinical depth → Low
Astellas (Veozah)
FDA approved May 2023 · ¥33.8B FY2024 revenue
Gedeon Richter (Ryeqo)
EU approved · NHS Mar 2025 · HUF 928.96B 2025 revenue
Bayer (Lynkuet)
FDA approved Oct 2025 · Peak sales forecast $1B+
Pfizer (Myfembree)
FDA approved · Co-developed with Myovant
Midi Health
Insurance-covered · Unicorn
$254M total
Alloy Women's Health
Virtual HRT
$16M Series A
Elektra Health
ACA health plan · HelloMeno Jan 2026
Embr Labs
Wearable VMS thermal therapy
Winona
DTC HRT · Growth stage
Evernow
DTC HRT
$52.5M total
Gennev
Aetna-covered · Pioneer platform
Stella
Holistic care · Seed/Series A
Stripes Beauty
Skincare · Growth stage
HerMD
Hybrid clinic · Growth stage
Consumer reach / DTC →